- $28.25bn
- $29.49bn
- $8.56bn
- 95
- 32
- 90
- 85
Annual income statement for Xylem, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4,876 | 5,195 | 5,522 | 7,364 | 8,562 |
| Cost of Revenue | |||||
| Gross Profit | 1,830 | 1,975 | 2,084 | 2,717 | 3,212 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4,509 | 4,608 | 5,039 | 6,713 | 7,599 |
| Operating Profit | 367 | 587 | 483 | 651 | 963 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 285 | 511 | 440 | 635 | 1,087 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 254 | 427 | 355 | 609 | 890 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 254 | 427 | 355 | 609 | 890 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 254 | 427 | 355 | 609 | 890 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 2.7 | 2.44 | 2.95 | 3.86 | 4.53 |
| Dividends per Share |